Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Hypercholesterolemia in the U.S.

Carlos Dujovne, MD, Professor of Medicine and Director
Carlos Dujovne, MD, Professor of Medicine and Director
OREGON HEALTH & SCIENCE UNIVERSITY - CC
Analysis of: Many Trial Reports on FDA-Approved Drugs Go Unpublished (www.washingtonpost.com)
This article is not news for clinical researchers like myself that have performed hundreds of clinical trials in collaboration with the Pharmaceutical Industry. Some of the most common reasons for that are: A)Negative studies are difficult to get published.B)Negative results for the dug of the...
Analysis of: Medicare overpaid on drugs with new generics, report says (www.latimes.com)
The Medicare drug system was a political ploy. This just confrims it. The private insurers were unwilling to offer Rx coverage before then because they understood the economics of it.
September 2, 2008
Byetta Saves Lives
Analysis of: FDA Alert: Hemorrhagic or Necrotizing Pancreatitis in Patients Taking Byetta (www.fda.gov)
1.Hypertriglyceridemia causes pancreatitis 2.Most PCP, endocrinologists, and cardiologists are not effectively treating high triglycerides, and may make it worse by recommending a low fat = high carb diet 3.Accord data with 75% reduction in death, and patients desparate for wt loss will continue to...
August 27, 2008
A rough in the diamond
Analysis of: FDA Alert: Hemorrhagic or Necrotizing Pancreatitis in Patients Taking Byetta (www.fda.gov)
If truly an association, this will alter the use of this drug.
Analysis of: Heart Stents No Better Than Drugs for Chest Pain Over Time (www.bloomberg.com)
Most hospitals are financially built on their heart programs. The "agressive" medical arm is conservative by our standards yet as good as stents at far less cost. If this was truly pursued by large companies with TPA insurance plans, their overall cost would drop with large savings in healthcare costs....
August 18, 2008
Byetta saves lives
Analysis of: Lilly Diabetes Drug Shows a Life-Extending Promise (www.nytimes.com)
The ACCORD trial results were no suprise to our diabetes practice. We have been heavy users of Byetta since launch in 2005, and have seen the same results in our population of > 2000 diabetics with over 700 on Byetta. Since the Simpson et al study in the Canadian Journal of Medicine (CMAJ 2006;174(2):169-74)...
Analysis of: Lilly Diabetes Drug Shows a Life-Extending Promise (www.nytimes.com)
The recent finding that Byetta therapy decreased mortality in the ACCORD study needs to be replicated in studies designed to address that point.  Even if it is replicated and statistically significant, it probably will not be true for the widely anticipated once weekly extended formulation...
Analysis of: Patients Curb Prescription Spending (online.wsj.com)
Given the economic pressures on patients, they are now more likely to ask for generic medications than they were in the past.  Given that there are generic versions of several classes of medications, physicians such as me are more likely to comply with a patient's request for a generic than in...
Analysis of: AstraZeneca and Bristol-Myers Squibb Submit New Drug Application in the United States and Marketing Authorisation Application in Europe for ONGLYZA™ (Saxagliptin) for the Treatment of Type 2 Diabetes (www.astrazeneca.com)
DDP4 inhibitor class fairly new.  Another arrow in the theraputic quiver
Analysis of: Drugs to Build Bones May Weaken Them (www.nytimes.com)
Patients may ask about this.  Haven't heard anyone yet.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 Next11 to 20 of 146

Analytics


Generated at 2009-01-07T19:00:58.307